Literature DB >> 28168823

OPO Strategies to Prevent Unintended Use of Kidneys Exported for High PRA (>98% cPRA) Recipients.

A S Paramesh1,2, N Neidlinger3, M Salvatore3, A Smith1, A Friedman4, W Payne5, T Taber6, C Wright7.   

Abstract

Since the advent of the Kidney Allocation System (KAS), matched candidates with high (>98%) panel reactive antibody (hPRA) are given priority over local candidates with lower PRA. This often leads to exporting of kidneys. Data for these kidneys are not detailed on routine reports. Twenty-two organ procurement organizations prospectively submitted data from August 2015 to July 2016, describing allocation practices of kidneys to hPRA patients and outcomes of these kidneys. Five hundred twenty out of 6924 procured kidneys were exported for hPRA recipients. Of these, 402 (77.3%) were transplanted into the intended recipient (IR); 100 (19.2%) were transplanted into unintended recipients (UR), and 18 (3.5%) were discarded. The most common reason for use in an UR was a positive crossmatch (XM) (63%). The most common reasons for discard were donor quality (44%) and ischemic time (39%). Prior to kidney export, when tissue crossmatching was done, 96.2% of the kidneys went to the IR, versus 80.7% following virtual CM, versus 56.7% when no crossmatching was performed (p < 0.0001). A significant number of kidneys exported for hPRA patients are not being used in the IR or are being discarded. The most common reason for this is positive tissue XM. We report that unintended use of the kidney was minimized when tissue was shipped and XM results were known prior to exporting the kidney.
© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  alloantibody; clinical research/practice; crossmatch; health services and outcomes research; histocompatibility; kidney transplantation/nephrology; organ allocation; organ procurement and allocation; organ procurement organization; panel reactive antibody (PRA)

Mesh:

Substances:

Year:  2017        PMID: 28168823     DOI: 10.1111/ajt.14220

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  2 in total

1.  Virtual Crossmatching in Kidney Transplantation, Shiraz Experience in Development of a Web-Based Program.

Authors:  N Jamshidian Tehrani; B Geramizadeh; S A Malekhosseini; S Nikeghbalian; A Bahador; S Gholami; G A Raees Jalali; J Roozbeh; M H Anbardar; N Soleimani; N Rasaei; S Mohammadzadeh
Journal:  Int J Organ Transplant Med       Date:  2021

2.  Trends and impact on cold ischemia time and clinical outcomes using virtual crossmatch for deceased donor kidney transplantation in the United States.

Authors:  Chethan M Puttarajappa; Dana Jorgensen; Jonathan G Yabes; Kwonho Jeong; Adriana Zeevi; John Lunz; Amit D Tevar; Michele Molinari; Sumit Mohan; Sundaram Hariharan
Journal:  Kidney Int       Date:  2021-04-30       Impact factor: 18.998

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.